Valuation dashboard for Precision BioSciences, Inc. (DTIL) with P/E N/A, P/B 3.78, EV/EBITDA -0.76 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases.
Analysis Summary
Precision BioSciences, Inc. reported revenue of $34.3M in the most recent fiscal year, growing at a 5-year CAGR of 7.1%.
Trailing-twelve-month margins: gross margin 100.0%, operating margin -80.8%, net margin -117.0%.
At the current price of $6.63, DTIL has negative trailing earnings (P/E not meaningful) and an ROE of -91.60%. Market capitalisation stands at $85M.
Balance sheet quality for DTIL: current ratio of 13.3. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 3.78 |
| EV / EBITDA | -0.76 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-11.73 |
| vs Current Price | -276.9% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| DTIL | Precision BioSciences, Inc. | $85M | 3.78 | -91.6% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $6.63 |
| Market Cap | $85M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -91.60% |
| Return on Invested Capital | -30.23% |
| Return on Assets | -41.88% |
| Gross Margin | 100.00% |
| Operating Margin | -80.78% |
| Net Margin | -117.04% |
Related companies: ABOS · ALEC · GOSS · HOOK · HRTX · KLDO · QTTB
Explore sector: Healthcare · Biotechnology
More sections of DTIL: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks